BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 31927044)

  • 1. Risk-reducing Bilateral Salpingo-oophorectomy: Assessing the Incidence of Occult Ovarian Cancer and Surgeon Adherence to Recommended Practices.
    Newcomb LK; Toal CT; Rindos NB; Wang L; Mansuria SM
    J Minim Invasive Gynecol; 2020; 27(7):1511-1515. PubMed ID: 31927044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health Care Provider Adherence to Surgical Guidelines for Risk-Reducing Salpingo-Oophorectomy.
    Wilhite AM; Oestreich MC; Olson M; Bedell SM; Westenberg D; Bangdiwala A; Ikramuddin S; Sanchez-Avila M; Madoff RD; Khalifa MA; Erickson BK
    Obstet Gynecol; 2019 Sep; 134(3):520-526. PubMed ID: 31403600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adherence to risk-reducing salpingo-oophorectomy guidelines among gynecologic oncologists compared to general gynecologists.
    Blustein P; Werner SR; Uppalapati P; Leung TM; Husk GA; Pereira EB; Whyte JS; Villella JA
    Am J Obstet Gynecol; 2023 Sep; 229(3):280.e1-280.e8. PubMed ID: 37308046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Practice variation in bilateral salpingo-oophorectomy at benign abdominal hysterectomy: a population-based study.
    Cusimano MC; Moineddin R; Chiu M; Ferguson SE; Aktar S; Liu N; Baxter NN
    Am J Obstet Gynecol; 2021 Jun; 224(6):585.e1-585.e30. PubMed ID: 33359174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surgical Findings and Outcomes in Premenopausal Breast Cancer Patients Undergoing Oophorectomy: A Multicenter Review From the Society of Gynecologic Surgeons Fellows Pelvic Research Network.
    Harvey LFB; Abramson VG; Alvarez J; DeStephano C; Hur HC; Lee K; Mattingly P; Park B; Piszczek C; Seifi F; Stuparich M; Yunker A
    J Minim Invasive Gynecol; 2018 Jan; 25(1):111-115. PubMed ID: 28821472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. "Best practices in risk reducing bilateral salpingo-oophorectomy: the influence of surgical specialty".
    Malacarne DR; Boyd LR; Long Y; Blank SV
    World J Surg Oncol; 2017 Dec; 15(1):218. PubMed ID: 29228967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Uptake and timing of risk-reducing salpingo-oophorectomy among patients with BRCA1 and BRCA2 mutations.
    Smith MJ; Gerber D; Olsen A; Khouri OR; Wang Y; Liu M; Smith J; Pothuri B
    Am J Obstet Gynecol; 2021 Nov; 225(5):508.e1-508.e10. PubMed ID: 34171390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ovarian cancer incidence and death in average-risk women undergoing bilateral salpingo-oophorectomy at benign hysterectomy.
    Cusimano MC; Ferguson SE; Moineddin R; Chiu M; Aktar S; Liu N; Baxter NN
    Am J Obstet Gynecol; 2022 Feb; 226(2):220.e1-220.e26. PubMed ID: 34563499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of high, moderate, and low penetrance ovarian cancer susceptibility mutations: an assessment of current risk reduction practices.
    Watson CH; Soo L; Davidson BA; Havrilesky LJ; Lee PS; McNally LJ; Previs RA; Secord AA; Berchuck A; Kauff ND
    Int J Gynecol Cancer; 2020 Oct; 30(10):1583-1588. PubMed ID: 32839226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing the Risk of Occult Cancer and 30-day Morbidity in Women Undergoing Risk-reducing Surgery: A Prospective Experience.
    Bogani G; Tagliabue E; Signorelli M; Chiappa V; Carcangiu ML; Paolini B; Casarin J; Scaffa C; Gennaro M; Martinelli F; Borghi C; Ditto A; Lorusso D; Raspagliesi F
    J Minim Invasive Gynecol; 2017; 24(5):837-842. PubMed ID: 28479170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.
    Kauff ND; Satagopan JM; Robson ME; Scheuer L; Hensley M; Hudis CA; Ellis NA; Boyd J; Borgen PI; Barakat RR; Norton L; Castiel M; Nafa K; Offit K
    N Engl J Med; 2002 May; 346(21):1609-15. PubMed ID: 12023992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. To oophorectomy or not to oophorectomy: Practice patterns among urologists treating bladder cancer.
    Sussman RD; Han CJ; Marchalik D; Carvahlo FL; Davis MF; Richter LA; Wethington SL; Stamatakis L
    Urol Oncol; 2018 Mar; 36(3):90.e1-90.e7. PubMed ID: 29273351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Attitudes of Israeli gynecologists towards risk reduction salpingo-oophorectomy at hysterectomy for benign conditions and the use of hormonal therapy.
    Assaf W; Andraous M; Lavie O; Segev Y
    Eur J Obstet Gynecol Reprod Biol; 2022 May; 272():48-54. PubMed ID: 35279641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcome of risk-reducing salpingo-oophorectomy in BRCA carriers and women of unknown mutation status.
    Manchanda R; Abdelraheim A; Johnson M; Rosenthal AN; Benjamin E; Brunell C; Burnell M; Side L; Gessler S; Saridogan E; Oram D; Jacobs I; Menon U
    BJOG; 2011 Jun; 118(7):814-24. PubMed ID: 21392246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inappropriate oophorectomy at time of benign premenopausal hysterectomy.
    Mahal AS; Rhoads KF; Elliott CS; Sokol ER
    Menopause; 2017 Aug; 24(8):947-953. PubMed ID: 28486247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breast cancer risk after hysterectomy with and without salpingo-oophorectomy for benign indications.
    Chow S; Raine-Bennett T; Samant ND; Postlethwaite DA; Holzapfel M
    Am J Obstet Gynecol; 2020 Dec; 223(6):900.e1-900.e7. PubMed ID: 32585221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short- and long-term outcomes for single-port risk-reducing salpingo-oophorectomy with and without hysterectomy for women at risk for gynecologic cancer.
    Carr CE; Chambers L; Jernigan AM; Freeman L; Escobar PF; Michener CM
    Int J Gynecol Cancer; 2021 Feb; 31(2):215-221. PubMed ID: 32948638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ACOG Committee Opinion No. 774 Summary: Opportunistic Salpingectomy as a Strategy for Epithelial Ovarian Cancer Prevention.
    Obstet Gynecol; 2019 Apr; 133(4):842-843. PubMed ID: 30913193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can we prevent ovarian cancer?
    Aus AT
    Ceska Gynekol; 2020; 85(1):49-58. PubMed ID: 32414285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know.
    Franceschini G; Di Leone A; Terribile D; Sanchez MA; Masetti R
    Ann Ital Chir; 2019; 90():1-2. PubMed ID: 30872561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.